Stock IFRX INFLARX N.V.
Add to a list
To use this feature you must be a member
Log inSign up

All News InflaRx N.V.

Equities

IFRX

NL0012661870

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
1.38 USD 0.00% Intraday chart for InflaRx N.V. +3.76% -15.34%
03-21 Transcript : InflaRx N.V. - Special Call
03-21 InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
AQ
InflaRx N : 20240425_Minutes 2024 AGM - InflaRx NV_signed
PU
InflaRx N : Deed of Amendment to the Articles of Association, dated April 25, 2024 - Form 6-K
PU
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
AQ
Transcript : InflaRx N.V. - Special Call
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
InflaRx N : News Conference Call March 2024
PU
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
AQ
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
AQ
InflaRx Appoints Jan Medina as Head of Investor Relations
AQ
InflaRx N.V. Appoints Jan Medina as Head of Investor Relations
CI
HC Wainwright Adjusts Price Target on InflaRx to $8 From $9, Keeps Buy Rating
MT
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
GL
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose Phase I Study with C5aR Inhibitor INF904
CI
Transcript : InflaRx N.V. - Special Call
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
AQ
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
AQ
InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
CI
Top Premarket Gainers
MT
InflaRx N : 11-2023-InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IFRX Stock
  4. News InflaRx N.V.